FDA Panel Won't Back Sanofi Blood Thinner For Cancer Patients

Law360, Washington (June 20, 2012, 1:54 PM EDT) -- A U.S. Food and Drug Administration advisory panel voted overwhelmingly Wednesday not to recommend approval of a Sanofi Aventis US LLC anticoagulant for cancer patients receiving chemotherapy, saying the company's main study didn't show the drug would significantly lower patients' blood clot risks.

In a 14-1 vote with one abstention, members of the FDA Oncologic Drugs Advisory Committee voiced concerns that if the agency approved blood thinning drug semuloparin, it could spark a change in cancer treatment practices since no other drug is specifically approved to...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.